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Abstract
A major part of the post-transcriptional regulation of gene expression is affected by trans-acting elements, such as
microRNAs, binding the 39 untraslated region (UTR) of their target mRNAs. Proliferating cells partly escape this type of
negative regulation by expressing shorter 39 UTRs, depleted of microRNA binding sites, compared to non-proliferating cells.
Using large-scale gene expression datasets, we show that a similar phenomenon takes place in breast and lung cancer:
tumors expressing shorter 39 UTRs tend to be more aggressive and to result in shorter patient survival. Moreover, we show
that a gene expression signature based only on the expression ratio of alternative 39 UTRs is a strong predictor of survival in
both tumors. Genes undergoing 39UTR shortening in aggressive tumors of the two tissues significantly overlap, and several
of them are known to be involved in tumor progression. However the pattern of 39 UTR shortening in aggressive tumors in
vivo is clearly distinct from analogous patterns involved in proliferation and transformation.
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Introduction
MicroRNAs and other trans-acting factors that bind mRNA
regulate protein levels by preventing mRNA translation and
inducing its degradation. The key role played by this mechanism
of post-transcriptional regulation in development [1] and disease
[2] is emerging from an ever growing body of experimental results.
Many individual microRNAs have been shown to be aberrantly
expressed in several types of cancer [2]. While some microRNAs
act as oncogenes, in most reported cases it is the loss of microRNA
expression that correlates with the onset or the aggressiveness of
the tumor. A picture emerges in which microRNAs keep cells from
inappropriately proliferating and invading the surrounding tissues
[3,4] by repressing the expression of their targets.
In a heterogeneous cell population, selection will favor the cells
that are able to escape such control. This can be done either by
suppressing the expression of the individual microRNAs or,
perhaps more efficiently, by interfering globally with the
mechanism of regulation by microRNAs, for example by
decreasing expression of genes involved in the microRNA pathway
such as DICER1 [5,6] or TARBP2 [7].
Another way of escaping microRNA control is to remove their
binding sites by expressing shorter transcripts: often this can be
achieved without altering the gene product since the microRNA
binding sites are mostly located within 39 untranslated regions.
Many mRNAs contain 39 UTRs with alternative polyadenylation
(APA) sites that can be used to produce transcripts of different
length (see e.g. the review [8]).
Indeed it was shown that proliferating cells [9], cancer cells
[10,11], early-stage embryonic cells [12,13] and induced plurip-
otent stem cells [14] express shortened 39 UTRs with fewer
microRNA binding sites. This way of escaping microRNA control
by removing binding sites in cis has the advantage of being more
fine-tunable than the removal in trans of the microRNA, as specific
mRNA targets can be selectively released from regulation.
We therefore asked whether the same phenomenon exists in
tumors, and in particular whether shorter 39 UTRs correlate with
tumor aggressiveness and shorter survival times. Such correlation
was previously shown in a mouse model of lymphoma in [15]. To
address this question we took advantage of the extensive cancer
gene expression datasets available in the public domain produced
with Affymetrix chips of the U133 generation, and including
patient survival and other clinical data.
While these chips were not originally designed for discriminat-
ing between alternative transcripts, they can be used [12] to
answer our question, at least partially. Indeed, on one hand, most
probes match the 39 region of the target transcripts and, on the
other, probes can be reorganized into user-defined probesets.
Exon arrays would be the obvious choice, but the number of large-
scale cancer datasets obtained with this platform is still limited.
We thus defined custom probesets matching 39 UTR regions
separated by APA sites: this turned out to be possible for thousands
of transcripts, for which we determined the relative expression of
the long and short forms of the 39 UTR in each patient. The
correlation between these data and patient survival could then be
studied to determine whether the expression of longer or shorter 39
UTRs correlates with cancer aggressiveness.
Results
Affymetrix chips of the HG-U133 series have been extensively
used in studies of gene expression in cancer. Several datasets are
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data and other clinical information. Most probes are located at the
39 end of the target transcript. Even though the single probes were
organized by the manufacturer in standard probesets, they can
also be reorganized into custom probesets [16], either to take
advantage of improvements in the annotation of the genome or to
perform special-purpose analyses. These features of the Affymetrix
chips were previously exploited in [12,14] to study 39 UTR
shortening in mouse development and in induced pluripotent stem
cells.
We created a custom Chip Description File (CDF), i.e. a custom
set of probesets, for the HG-U133A, HG-U133B and HG-
U133_Plus_2 chips, matching alternative transcripts that differ in
the portion of the 39UTR they express. Alternative transcripts of
this type are generated using APA sites, whose location can be
predicted by sequence analysis and comparison with cDNA/EST
sequences. We used the polyA_DB database [17,18] to obtain a
collection of predicted APA sites.
Given a transcript with an APA site, we divided the Affymetrix
probes matching the transcript into two sets, 59 and 39 probes,
relative to the APA site. We then created separate probesets from
the 59 and 39 probes. The software package we used [16]
recommends creating probesets containing at least three probes.
With this criterion, we could build separate 59 and 39 probesets for
2,706 transcripts represented in the HG-U133A and HG-U133B
chips. For 685 transcripts it was possible to create 59 and 39 probes
for more than one APA sites.
The long version of a transcript will hybridze with both the 59
and 39 probes, while the short version generated by the APA site
will hybridize only with the 59 probes. Denoting with eL (eS) the
expression level of the long (short) form, the signal from the 59
probeset will be
S5’~aLeLzaSes ð1Þ
where aL,S represent the affinities of the long and short forms for
the 59 probeset. Similarly the signal from the 39 probeset will be
S3’~bLeL ð2Þ













is a linear function of the expression ratio between the two
alternative transcripts, and can be used to study their relative
prevalence. On the other hand an overall change of expression of
the transcript, which does not alter the relative amounts of the two
forms, does not change the ERI value.
We can thus compare the ERI values in two biological samples
to determine whether the long and short forms of the transcript are
expressed in different ratios. A higher ERI correponds to a higher
prevalence of the short form.
Comparison with PCR-based results
We validated the use of the ERI to infer relative expression of
long and short 39 UTR forms by comparing the PCR-based data
reported in Ref. [10] in various cancer cell lines to microarray data
obtained on HG-U133_Plus_2 array on some of the same cell lines
and available from GEO repository accession GSE10843.
For 4 of the 6 genes shown in Figure 2 of [10] we could build
separate probesets for the regions upstream and downstream of
the relevant APA site (CCND1, CCND2, IGF2BP1, RAB10). For
FGF2 and DICER1 this was not possible, because all Affymetrix
probes lie distal to the APA site. Incidentally, this shows that
expression data for these genes obtained with HG-U133
platforms must be interpreted with great caution, because the
microarray cannot hybridize to the transcript expressing the
shorter 39 UTR form, which might very well be the one
associated with higher protein expression. The relevant probes
are shown in Figure 1.
As explained above, we expect the ERI to be a linear function of
the expression ratio of short vs. long 39UTR. Therefore we expect
the ERI as computed from microarray data to correlate positively
with direct measurements of expression ratios (in the absence of all
experimental variability and noise we would expect a Pearson
correlation coefficient equal to 1). The authors of [10] report in
their Figure 2 the expression ratios of short vs. long 39UTR for
several cell lines originating from breast, colon and lung tumors.
Each ratio is normalized to the same ratio in the corresponding
normal tissue: therefore we computed, separately for each tissue of
origin and each of the four genes, the Pearson correlation
coefficient between the ERI derived from the micorarray data and
the normalized ratio reported by [10], computing a total of 6
correlation coefficients. All of them turned out to be positive
(P~0:016, binomial test), varying between 0.34 for CCND1 in
lung cancer cells and w0:99 for CCND1 in breast cancer cells.
These results convinced us that the ERI we defined can indeed be
used to probe the differential expression of alternative 39 UTR
forms.
Comparison with high-throughput sequencing results
To validate the method also at a more global scale we compared
its results to those obtained on breast cancer cell lines using high-
throughput sequencing in a recent publication [11]. Here the
authors studied differential APA usage between two breast cancer
cell lines (MDA-MB-231 and MCF7) and a cultured mammary
epithelial cell line (MCF10A).
We used microarray data for the three cell lines available
from the GEO database under accession GSE10890, and
selected untreated samples of the three cell lines of interest (7
samples for each cancer cell line and 2 samples of MCF10A).
The platform used here is the HG-U133_Plus_2, for which we
could build separate 59 and 39 probesets for 6,045 APA sites in
3,542 unique genes. For each APA site and each pair of cell
lines we identified differential APA usage with a t-test on the
ERI values followed by multiple testing correction with the
Benjamini-Hochberg procedure and a False Discovery Rate
( F D R )c u t o f fo f5 % .
We thus obtained lists of genes with significantly shortened or
lengthened 39 UTR for the three possible comparison, thus a
total of 6 lists, to be compared with the analogous lists compiled
from high-throughput sequencing in [11]. The overlap turned
out to be statistically significant (Pv0:05) in 5 out of 6 cases, the
most significant one corresponding to 39 UTRs that are
shortened in MDA-MB-231 cells compared to MCF7 cells (318
genes concordantly detected by microarray and sequencing,
compared to 227 expected by chance, P~2:7:10{17,e x a c t
Fisher test). The only case in which the overlap was not
statistically significant was 39 UTRs that are lengthened in
MCF7 cells compared to MCF10A, which is also the least
common case according to both approaches. We concluded that
our method, when used on a genome-wide scale, gives results
that are in good agreement with unbiased approaches such as
high-throughput sequencing.
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PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31129Figure 1. Affymetrix probes and APA sites in the 39 UTR of six genes studied in Ref. [10]. The probes shown in red are used, possibly
together with probes located in the coding region, to build the 59 probeset. The probes shown in green are used to build the 39 probeset. For DICER1
and FGF2 it is not possible to study the APA site since all probes lie beyond it.
doi:10.1371/journal.pone.0031129.g001
Figure 2. Predictive power of the prognostic score based on ERI in two dataset not used to derive the signature. (A) the Miller breast
cancer dataset [20] and (B) the Shedden lung cancer dataset [32]. Patients are divided into groups using the median score as a cutoff.
doi:10.1371/journal.pone.0031129.g002
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shorter 39 UTRs
Using the strategy described above, we evaluated the relative
expression of long and short 39 UTR forms in a large, population-
derived dataset of 159 cases of breast cancer in which gene
expression profiles were measured using both HG-U133A and
HG-U133B platforms [19], which we will refer to as the Pawitan
dataset.
We divided the patients into two groups based on outcome
(relapse) at 5 years. The large sample size allowed us to use a non-
paramteric test, so we replaced the t-test used for cell lines with a
Mann-Whitney U test to find the transcripts for which the ERI is
significantly different between the two groups, i.e. the transcripts
for which the relative prevalence of long and short forms of the 39
UTR differs between the two groups of patients. After correcting
for multiple testing using the Benjamini-Hochberg procedure we
found, at 5% FDR, 35 APA sites in 28 different transcripts for
which the relative expression of the short and the long form is
significantly different between the two outcome groups (Table S1).
Of these, 34 showed higher short/long expression ratio in the
poor-outcome group and only one showed the opposite behavior:
we conclude that, globally, the expression of shorter 39 UTRs
correlates with poor outcome, in qualitative agreement with results
obtained from cell lines [10].
A prognostic signature based on APA site usage
These results suggest that the relative prevalence of the short
and long forms of the 35 APA sites can be used to stratify patients
into risk classes. We thus developed a prognostic score based on
the ERI of these APA sites. The prognostic score of a patient was
defined as a linear combination of the ERI values of the 35 sites in
the signature. The coefficients in the linear combination are
determined from Cox univariate analysis as detailed in the
Methods. Patients with high prognostic scores are characterized by
relatively higher expression of the isoform associated to poor
outcome (the short form for all but one APA site).
The prognostic score can be used to separate patients in two
groups based on a cutoff. When applied to the Pawitan dataset,
using the median score as a cutoff, the two groups of patients are
significantly different in survival probability (P~1:99:10{7, log-
rank test). This is however expected, since the APA sites in the
signature were chosen based on their differential ERI in the same
dataset.
We thus used an independent, population-derived breast cancer
dataset of 236 samples measured with the same platforms [20], the
Miller dataset, to verify the robustness of the prognostic signature.
The prognostic score of each patient of this dataset was computed
as in the case of the Pawitan dataset, and the median score was
used to divide the patients into two groups. Importantly, the
coefficients used were the ones derived from the Pawitan dataset,
so that the Miller dataset was not used at all in determining the
signature. The two groups of patients differed significantly in
disease-specific survival probability (P~6:28:10{3, Figure 2A).
Therefore the short/long expression ratio of the 35 APA sites
identified in the Pawitan dataset can be used to create a robust
outcome predictor based exclusively on the relative prevalence of
alternative 39 UTRs.
Differential synthesis vs. differential degradation
The observed higher ERI in poor-outcome tumors could be due
either to altered ratios in the synthesis of the two isoforms, or to
altered degradation rates. As an example of the latter mechanism,
assume a microRNA, able to bind the long isoform of a transcript
but not the short one, is expressed at higher levels in poor-outcome
tumors. Then even if the two isoforms are synthesized at the same
rate, the long one will be degraded faster in the poor-outcome
tumors, leading to higher ERI. At least in the simplest case in
which only one of the two mechanisms is at work it is possible to
distinguish between them by looking at the differences in the total
expression of the transcript between poor- and good-outcome
cases (Figure 3).
First suppose differential synthesis is involved, i.e. relatively more
of the short form is synthesized in poor-outcome tumors. Then the
decay rate in this class of tumors will be lower, because of the loss
of microRNA binding sites: hence we expect a higher total
expression of the transcript in poor-prognosis tumors.
On the contrary, if the ratio of synthesized isoforms is the same
in the two classes of tumors, but microRNAs able to degrade the
transcript are more abundant in the poor-outcome cases, we
expect higher degradation rates in the latter class, and thus lower
total expression of the the transcript in poor-prognosis tumors.
Since the probes located 59 of the APA site are able to hybridize
to both isoforms, they can be used to evaluate the total expression
of each transcript. Therefore we can distinguish between the two
cases by looking at the correlation between differences in ERI and
differences in signal from the 59 probesets: if differential synthesis
(degradation) is the dominant mechanism, we expect positive
(negative) correlation between these two quantities.
We thus computed, for each transcript, the difference in median
expression of the 59 probeset between poor- and good-outcome
tumors, and its correlation with the difference in median ERI. To
avoid overcounting transcripts with more than one APA site we
included only the 59-most site for each transcript. We obtained a
positive and highly significant Spearman correlation coefficient
(rS~0:30, P~4:1:10{58). While this analysis is based on a
simplified model, it suggests differential synthesis is a significant
mechanism leading to 39 UTR shortening in aggressive tumors.
39 UTR portions containing microRNA binding sites are
preferentially lost in aggressive tumors
If the expression of shorter 39 UTRs confers a selective
advantage by allowing escape from microRNA-mediated repres-
sion, we expect the 39 UTR portions containing microRNA
binding sites to be lost in aggressive tumors more often than those
which do not contain them. To test this expectation we defined as
‘‘microRNA-relevant’’ the APA sites removing at least one
predicted microRNA binding site from the transcript. For each
APA site, we took the difference in mean ERI between poor- and
good-prognosis tumors as a measure of 39 UTR shortening:
microRNA-relevant sites showed significantly more shortening
than irrelevant ones (P~3:3:10{9, Mann-Whitney U test). Thus
the shortening of 39 UTRs in aggressive tumors is more
pronounced for those transcripts for which it leads to loss of
microRNA binding sites.
The same analysis can be performed for individual microRNAs,
by comparing APA sites that are relevant, in the sense defined
above, for specific microRNAs to irrelevant ones. At 10% FDR we
found 5 microRNAs significantly associated with 39 UTR
shortening in aggressive tumors: miR-7, miR-96, miR-200bc/
429, miR-299-5p and miR-496. No microRNA was significantly
associated with 39 UTR shortening in good-prognosis tumors.
Since these are the microRNAs whose regulatory activity is
partly suppressed by the removal of their binding sites in shortened
39 UTRs, we would expect the microRNA themselves to have
tumor-suppressor activity. Indeed three of these microRNAs were
previously shown to have such effect in breast cancer cell lines: the
miR-200bc/429 family negatively regulates EGF-driven cell
Shortening of 39UTRs in Aggressive Cancers
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the epithelial to mesenchymal transition [22]; tumor suppressor
activity of miR-7 in breast cancer cell lines was shown in [23,24],
and its role in preventing resistance to chemotherapy in [25,26]
(note, however, that miR-7 correlates with poor prognosis in a
specific molecular class of breast cancer [27]); decreased
expression of miR-299-5p was associated to increased tumorigenic
potential [28]. Our results suggest that cancer cells can overcome
Figure 3. Schematic representation of two possible mechanisms leading to higher ERI in poor-prognosis tumors. (A) Differential
synthesis: the shorter isoform is synthesized in a higher proportion in the poor-prognosis tumors, leading to less degradation by microRNAs. (B)
Differential degradation: the isoforms are produced in the same proportion in the two cases, but a microRNA expressed exclusively in the poor-
prognosis tumors selectively degrades the long isoform. In both cases we expect a higher ERI (relative prevalence of short form) in the poor-
prognosis group. However in case (A) the overall expression of the two isoforms is expected to be higher in the poor-prognosis case, while the
opposite is expected in case (B).
doi:10.1371/journal.pone.0031129.g003
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expression, but also by preventing them from binding to their
targets.
More puzzling is the appearance of miR-96, which, on the
contrary, was shown to have proliferation-promoting activity by
repressing FOXO transcription factors [29,30]. However, as
discussed above, the effect of removing selected targets from
microRNA control can be vastly different from the effect of simply
removing of repressing the microRNA itself.
Comparison with results in cell lines and normal tissues
Since 3UTR shortening has been previously associated to
proliferation, one possibility to explain the specific effects that we
detected could be the increased proliferation that characterizes
aggressive tumors. Therefore we asked to what extent the
transcripts showing differential APA usage in poor vs. good-
prognosis patients coincide with those found in recent genome-
wide studies of APA usage in normal and cancer cell lines.
However, no significant overlap was found between the 28
transcripts involved in our breast cancer signature and the 980
mouse transcripts showing differential APA usage in mouse
activated lymphocytes [9].
The same lack of statistically significant overlap was found when
comparing our results to the ones obtained comparing different
breast cancer cell lines to a normal breast cell line in [11]. Such
negative result holds also when using our own microarray-derived
results for the same cell lines (from the same dataset GSE10890
used above to check our algorithm), suggesting that the lack of
overlap is not due to different biases between sequencing- and
microarray-based measurements.
On the contrary, a pattern of differential 39 UTR usage similar
to the one we find in aggressive vs. less aggressive breast tumors is
found when comparing breast tumor samples (independently of
aggressiveness) to healthy tissue: using the data of Ref. [31]
(accession GSE3744 in GEO) we compared 38 sporadic tumor
samples to 7 normal breast samples. We observed, as expected, a
large number of APAs displaying 39 UTR shortening in cancer vs
normal tissues (1,222 APAs corresponding to 921 unique genes at
5% FDR) and only 212 APAs (189 genes) showing the opposite
behavior. The platform used here is the HG-U133_Plus_2, which
allows us to analyze a total of 4,933 APAs (3,452 genes). The genes
undergoing 39 UTR shortening significantly overlap with the ones
found above from the Pawitan dataset (21 genes in common
compared to 6.98 expected by chance, P~2:1:10{8).
Therefore while widespread 39 UTR shortening is observed in
many different contexts, all generically related to increased
proliferation, the transcripts involved are significantly different in
the different contexts, even within the same tissue of origin. In
particular we observe similar patterns of 39 UTR shortening when
comparing breast tumors to normal tissues and when comparing
breast tumors of different aggressiveness: however this pattern is
markedly different from what observed in breast cancer cell lines,
suggesting that the use of cancer cell lines in studying this
particular phenomenon might not be ideal.
39 UTR shortening in aggressive lung cancer
We asked whether the pattern of 39UTR shortening found in
aggressive breast tumors was specific of breast cancer or relevant
to other tumors. Specifically we considered a large lung cancer
dataset [32], containing expression profiling of more than 400 lung
adenocarcinomas. The 35-APA signature found in breast cancer
turned out to be predictive of survival also in these patients: when
computing the prognostic score of each patient using the signature
and dividing them into two groups using the median score as cutoff
we found a significant difference in patient survival
(P~9:33:10{4, Figure 2B). This result suggests that the pattern
of 39 UTR shortening in aggressive lung cancer is similar to the
one observed in breast cancer.
Therefore we repeated the analysis leading to the breast cancer
signature directly on the lung cancer dataset. To account for the
shorter overall survival of lung cancer patients we defined the
poor-prognosis group to include all patients who died of the
disease within 30 months. At 5% FDR we found a total of 319
APA sites with differential usage between good- and poor-
prognosis patients (Table S2): in 258 (81%) of these the shorter
isoform is predominantly expressed in poor-prognosis patients.
The overlap between the breast and lung cancer results is highly
significant: 11 genes (Table 1) show significant 39 UTR shortening
in poor-prognosis patients of both cancers, compared to an
overlap of 2.4 genes expected by chance (P~6:7:10{6). This
result is surprising given the lack of significant overlap with results
in cell lines discussed above, and suggests the existence of a specific
program of 39 UTR shortening associated with tumor aggressive-
ness in different tissues. This program is, on one hand, largely
shared between breast and lung tumors, and, on the other, clearly
distinct from analogous programs associated with physiological
proliferation [9] and cell transformation [11].
A first interesting observation about these genes is that many of
them have been positively implicated in breast and/or lung cancer
progression and resistance to therapy: AURKA [33,34], CAV2 [35],
RAB27A [36], RAD51 [37–39], TIMELESS [40], TIMM17A [41].
On the other hand there is evidence of a tumor-suppressing role of
SPARC [42,43].
The available information about the function of these genes
suggests that one of the mechanisms by which they may promote
cancer aggressiveness could be through increasing cell migration
and invasiveness. Indeed, the overexpression of AURKA in breast
cancer cells has been reported to increase cell migration through
ADF/cofilin pathway [33]. A related action on cytoskeleton could
be exerted by CACYBP [44], although the results for its
implication in breast cancer are seemingly contradictory [45,46].
Caveolins are well known modulators of cell motility and
migration [47] and are significantly overexpressed in breast
cancer cells characterized by basal-like and triple-negative
immunophenotype [48]. RAB27A was shown to confer invasive
and metastatic phenotypes on breast cancer cells by promoting the
Table 1. Genes showing significant 39 UTR shortening in
poor-prognosis patients of both breast and lung cancer.
Gene Symbol Gene
ARL1 ADP-ribosylation factor-like 1
AURKA aurora kinase A
CACYBP calcyclin binding protein
CAV2 caveolin 2
CENPN centromere protein N
KIAA0101 KIAA0101
RAB27A RAB27A, member RAS oncogene family
RAD51 RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae)
SPARC secreted protein, acidic, cysteine-rich (osteonectin)
TIMELESS timeless homolog (Drosophila)
TIMM17A translocase of inner mitochondrial membrane 17
homolog A (yeast)
doi:10.1371/journal.pone.0031129.t001
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influences the synthesis of extracellular matrix, elicits changes in
cell shape, inhibits cell-cycle progression [49]. An even more
striking observation is that three gene in the list, i.e. AURKA
[50,51], KIAA0101 [52] and RAD51 [53–55] are localized to
centrosomes, may affect centrosome duplication and are capable
to physically or functionally interact with the tumor suppressor
gene BRCA1. A strong role in control of genomic stability for the
genes in our signature is further indicated by the facts that
CENPN is a factor required for centromere assembly [56] and that
TIMELESS plays a crucial role in the ATM/ATR growth arrest
response induced by DNA-damage and in the G2/M checkpoint
[57].
Extension to other datasets and tumor types
To further investigate the robustness and general applicability
of the two signatures derived from breast and lung cancer
datasets we applied them to several other datasets available from
GEO and for which both CEL files and survival data are
available. Using the breast cancer-derived signature of 35 APAs
we systematically observe, with the only exception of the colon
cancer dataset of Ref. [58], shorter survival for high-scoring
patients, even if this difference reaches statistical significance only
in some cases (Figure S1). Also in this case the signature was built
using the APAs and the coefficients derived from the Pawitan
breast cancer dataset. In particular for breast cancer we observe
that statistical significance is reached for the datasets including
lymph-node positive patients [19,20,59], but not for those
including only lymph-node negative patients [60,61]. This might
suggest that shortening of 39 UTRs becomes important in the
advanced stages of the disease. The lung-cancer derived signature
shows similar results, but appears to be significantly less robust
(Figure S2).
Discussion
We have shown that 39UTR shortening in specific mRNAs
correlates with poor prognosis in both breast and lung cancer, and
that a significant part of this phenomenon is attributable to
differential synthesis of alternative isoforms rather than to their
differential degradation. Several genes involved in tumor progres-
sion and resistance to therapy express shortened 39 UTRs in
aggressive tumors, supporting the notion that tumor cells gain an
evolutionary advantage by removing these genes from the control
of trans-acting regulators acting on the 39 UTR.
The fact that 39 UTRs are globally shorter in aggressive tumors
could be expected, since shortening of 39 UTRs in various
proliferative contexts have been reported in the literature [9–15].
However our analysis shows that there are specific patterns of 39
UTR shortening for different proliferative contexts. In particular
the pattern of 39 UTR shortening associated to aggressive breast
and lung cancer does not overlap significantly with what is
observed in proliferating T cells [9] or even in breast cancer cell
lines [11]. Since the latter negative result is obtained also when
cancer cell lines are analyzed with the same microarray-based
method used for cancer patients, it is unlikely to be artefactual.
These results suggest that cancer cell lines might not be a suitable
environment to study alternative APA usage in cancer, in
agreement with the results of [11].
It is therefore all the more striking that, on the contrary, there is
a significant overlap between between genes undergoing 39 UTR
shortening in aggressive breast and lung cancer. We thus suggest
the existence of a specific pattern of 39 UTR shortening associated
with tumor aggressiveness, significantly shared between breast and
lung cancer, but clearly distinct from other such patterns
associated with proliferation and transformation.
The available information about genes that compose this shared
signature is very well consistent with their causal involvement in
the increased aggressiveness of tumors. Indeed, the expression
variation resulting from variation of their 39-UTR length could, on
one hand, affect their invasive properties and, on the other hand,
affect their propensity to undergo centrosome amplification,
aberrant mitosis and resistance to DNA damage. Considering
that AURKA can play a role in all these processes [33,50,51], our
results further underscore its importance as a critical pharmaco-
logical target for preventing cancer progression.
Individual cis-acting genetic hits involved in 39 UTR shortening
in cancer have been documented. For example in 7 out of 15 cases
of mantle cell lymphoma expressing a truncated CCND1 mRNA
[62] a genomic deletion in the 39 UTR region was detected, and in
3 other cases a point mutation led to the creation of premature
polyadenylation sites. However the effect we observed seems to
involve too many genes to be explained solely or predominantly in
this way. Many regulatory programs involving alternative usage of
APA sites in various physiological contexts have been demonstrat-
ed, so that it appears likely that cancer cells could exploit a similar
program to gain an evolutionary advantage.
Such a mechanisms would involve the binding of trans-acting
factors to specific sites in the vicinity of the polyA site, as shown for
example in [63] where it was shown that differential polyA usage
in different human tissues correlates with overrepresentation of
specific cis-elements. However a similar analysis in our case did
not reveal any statistically signifcant pattern. This could be due
either to a lack of statistical power (possibly related to the limited
number of transcripts we can study) or to the fact that the relevant
cis-elements in the case of cancer recognize structural rather than
sequence features.
The most significant limit of the approach we presented here is
the use of 39-based chips. This choice was due to the large
availability of gene expression profiles with survival information,
but severely limits the number of genes that can be analyzed (up to
*3,500 for the HG-U133_Plus_2 platform). We have shown that
the alternative 39 UTR usage of these genes can be reliably
inferred from the microarray data and that it is biologically and
clinically relevant; however since we cannot assume these genes to
be an unbiased subset of the whole genome, all inferences about
the global pattern of alternative 39 UTR usage must be taken with
great caution. Future work based on RNA-sequencing or exon
arrays will be needed to study the overall usage of alternative 39
UTRs in aggressive tumors in a less biased way.
Moreover, the analysis of datasets combining expression
profiling and cancer genome sequencing data will determine what
proportion of the effect is due to individual genetic hits and to
changes in the regulation of mRNA polyadenylation and cleavage.
Identification of possible trans-acting factors that may mediate the
tumor progression-specific 39 UTR shortening that we here
described could potentially lead to novel therapeutic targets.
Methods
Generation of custom Chip Description Files
The sequence of all human mRNAs included in Refseq
database was obtained from the UCSC genome browser. Form
the same source we obtained the location of tha APA sites
identified in the polyA_DB database [17,18]. Each APA site was
used to divide a mRNA sequence into two fragments (59 and 39 of
the APA site). These fragments were then used as input for the
Bioconductor package ‘‘altcdfenvs’’ [16], which generates the
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with a custom CDF if the raw data (CEL files) are available.
Evaluation of 39 UTR shortening
Expression data for the 59 and 39 probesets included in the
custom CDF were obtained using Robust Multi-Array Average
(RMA) [64]. For each APA site and each biological sample, we
computed the Expression Ratio Index (ERI) defined in Eq. 3 as
the ratio of RMA expression values. A software package
containing the custom CDF files and an R script to compute the
ERIs is provided as Software S1).
A Mann-Whitney U test was used to determine which APA sites
showed significantly different ERI between the two group of
patients (defined on the basis of survival status at 5 years in breast
cancer and 2.5 years in lung cancer). Multiple testing was
controlled with the Benjamini-Hochberg procedure.
Prognostic score based on alternative 39 UTR usage
To define a prognostic score based on ERI values we first
computed, for each of the 35 APA sites differentially used in the
Pawitan dataset, its Cox univariate score z. This score measures
the correlation between a continuous quantity (in our case the
ERI) and patient survival. A positive (negative) z implies a negative
(positive) correlation between ERI and survival.





where the sum is over the 35 APA sites, zA is the Cox score and
ERIA is the ERI value of the APA. High-scoring patients are thus
characterized by high ERI values (i.e. high prevalence of the short
39 UTR isoform) for those APA sites that are most strongly
correlated to poor survival. The zA values for the 35 APA sites can
be found in Table S1.
The prognostic score of each patient in each dataset was
computed using Eq. 4, in which the zA coefficients are always the
ones derived from the Pawitan datasets. The predictive power of
the prognostic score was evaluated in each dataset by dividing the
patients into two groups using the median score as cutoff, and
using a log-rank test to compare the cumulative survival
probabilities of the two groups.
Cancer datasets
The cancer datasets we used for developing and testing the
prognostic signatures were all downloaded from the Gene
Expression Omnibus (GEO) repository, with the exception of
the lung cancer dataset of [32] which was obtained from the
caArray repository (https://array.nci.nih.gov/caarray/). We used
a total of 6 breast cancer datasets (GSE7390 [61], GSE20685 [65],
GSE3494 [20], GSE1456 [19], GSE2990 [59], GSE2034 [60]),
one colon cancer dataset (GSE14333 [58]), three lung cancer
datasets (the Shedden dataset mentioned above plus GSE3141
[66] and GSE14814 [67]) and one melanoma dataset (GSE22138
[68]).
Prevalence of microRNA binding sites in shortened 39
UTRs
An APA site was defined to be relevant to a specific microRNA
if the sequence located 39 of the site contained one or more
binding site predicted by Targetscan [69], as reported in the
corresponding UCSC track. An APA site was defined to be
microRNA-relevant if it was relevant to one or more specific
microRNAs. The ERI values of microRNA-relevant vs. irrelevant
APA sites were compared using a Mann-Whitney U test, with
multiple testing controlled with the Benjamini-Hochberg proce-
dure.
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